Brainomix has partnered with Boehringer Ingelheim to enhance the care of patients with fibrosing lung disease in the United States.
The collaboration will use Brainomix’s AI software, Brainomix 360 e-Lung, to analyze routine CT scans, aiming to speed up diagnosis and improve treatment access for patients with fibrosing lung disease. This condition, which is progressive and life-limiting, often goes undiagnosed for up to two years, significantly affecting patient survival rates.
The partnership will deploy the FDA-cleared e-Lung software across leading US pulmonology centers and their networks. The goal is to validate the software’s effectiveness in improving care pathways and patient outcomes.
Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, highlighted the importance of early diagnosis. “The current patient pathway for fibrosing lung disease often leads to significant delays in diagnosis. This partnership aims to create a network model of care to initiate treatment earlier and improve patient outcomes.”
Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim, noted the potential impact of the AI technology. “Early detection of disease progression is crucial for patients with fibrosing lung disease. The integration of Brainomix’s AI technology into the diagnostic process may help make earlier treatment decisions and improve patient quality of life.”
The partnership follows the recent FDA clearance of Brainomix 360 e-Lung in May 2024. New studies presented at the American Thoracic Society (ATS) Conference in San Diego have highlighted the prognostic value of Brainomix’s lung imaging biomarkers.